Supplementary Table S2 from Ibrutinib and PD-1 Blockade Potentiate Mesothelin-Targeting CAR T-cell Therapy in Preclinical Models of Pancreatic Cancer

Alexander Armstrong; Graziella van der Plancke; Sae Nishiguchi; Diego Salas‐Benito; Amanda A. Bouffard; Sadie Goncalves; Ashlyn T. Merce; Christopher Kelly; Filippo Birocchi; Sangwoo Park; Mark B. Leick; Nora Horick; Trisha R. Berger; Marcela Valderrama Maus; Giulia Escobar

doi:10.1158/1078-0432.31248839

Supplementary Table S2 from Ibrutinib and PD-1 Blockade Potentiate Mesothelin-Targeting CAR T-cell Therapy in Preclinical Models of Pancreatic Cancer

2026 Open access

Read full text

Authors: Alexander Armstrong, Graziella van der Plancke, Sae Nishiguchi, Diego Salas‐Benito, Amanda A. Bouffard, Sadie Goncalves, Ashlyn T. Merce, Christopher Kelly, Filippo Birocchi, Sangwoo Park, Mark B. Leick, Nora Horick

+3 more

Trisha R. Berger, Marcela Valderrama Maus, Giulia Escobar

DOI: 10.1158/1078-0432.31248839

Cited by: 0

Abstract

Supplementary Table 2. The results of the statistical analysis used to assess additive vs synergistic effect of ibrutinib in combination with CAR-T cells is shown for Fig 4H.

Fields of Study & Subjects

CAR-T cell therapy research Pancreatic and Hepatic Oncology Research Cancer Immunotherapy and Biomarkers

Publication details

Publication date: 4 February 2026